How can we realize the promise of personalized antidepressant medicines?
Personalized medication that is based on pharmacogenetic data has long been expected to improve the efficacy of treatments for neurological and psychiatric disorders, including depression. However, the complexity of the regulation of gene transcription and its interactions with environmental factors means that straightforward translation of individual genetic information into tailored treatment is unlikely. Nevertheless, when data from genomics, proteomics, metabolomics, neuroimaging and neuroendocrinology are used in combination, they could lead to the development of effective personalized antidepressant treatment that is based on both genotypes and biomarkers. This process will require many further steps and collaboration between basic and clinical neuroscience.
Holsboer
Florian
F
Max Planck Institute of Psychiatry, Kraepelinstrasse 2-10, 80804 Munich, Germany. holsboer@mpipsykl.mpg.de
D000928:Antidepressive Agents / Q000494:pharmacology*; D001923:Brain Chemistry / Q000187:drug effects / Q000235:genetics; D003866:Depressive Disorder / Q000188:drug therapy* / Q000235:genetics* / Q000503:physiopathology; D015195:Drug Design; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease / Q000235:genetics*; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D033183:Interdisciplinary Communication; D009488:Neurosciences / Q000379:methods / Q000639:trends
D000928:Antidepressive Agents; D005819:Genetic Markers